For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260302:nRSB9864Ua&default-theme=true
RNS Number : 9864U EKF Diagnostics Holdings PLC 02 March 2026
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Total Voting Rights
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, in accordance with the Financial Conduct Authority's Disclosure and
Transparency Rules, announces that the total issued share capital of the
Company consists of 431,963,112 ordinary shares of 1p each in the capital of
the Company ("Ordinary Shares"), of which 141,000 Ordinary Shares are held in
treasury. Therefore, the total number of Ordinary Shares carrying voting
rights will be 431,822,112.
The above figure of 431,822,122 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure and Transparency
Rules.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
Julian Baines, Executive Chair via Walbrook PR
Gavin Jones, Chief Executive Officer
Singer Capital Markets (Nominated Adviser & Broker) Tel: +44 (0)20 7496 3000
Phil Davies / Patrick Weaver
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )
EKF is an AIM-listed global diagnostics business focussed on:
● Point-of-Care analysers in the key areas of Hematology and Diabetes
● Life Sciences services provide specialist manufacture of enzymes and custom
products for use in diagnostic, food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TVREASDAEEPKEFA
Copyright 2019 Regulatory News Service, all rights reserved